Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-277793
Filing Date
2025-11-12
Accepted
2025-11-12 16:40:02
Documents
45
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tennx-20250930.htm   iXBRL 10-Q 1542500
2 EX-31.1 tennx-ex31_1.htm EX-31.1 16592
3 EX-31.2 tennx-ex31_2.htm EX-31.2 17043
4 EX-32.1 tennx-ex32_1.htm EX-32.1 9940
5 EX-32.2 tennx-ex32_2.htm EX-32.2 10283
  Complete submission text file 0001193125-25-277793.txt   4836658

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tennx-20250930.xsd EX-101.SCH 541582
47 EXTRACTED XBRL INSTANCE DOCUMENT tennx-20250930_htm.xml XML 721601
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34600 | Film No.: 251473646
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)